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The first French clinical trial using human embryonic stem cells for regenerative
purposes was launched in 2014, using the I6 stem cell line that was imported
from Israel. From Israel to France, national reproductive policies and practices
inform how basic scientists produce, manage and circulate cells across
countries. Building on an interdisciplinary co-production involving two social
scientists and a life scientist, this article suggests that biobanks passage cells
from in vitro fertilization to stem cell science and from country to country by
modifying their reproductive meaning. Four passages are described: the
absence of cells in 2005 when the research started in France; the presence of
supernumerary embryos available for research in Israeli IVF biobanks; the
production of the I6 stem cell bank in Israel; the importation and laboratory
biobanking of the cells in France. Human embryonic stem cell lines can never
be completely disentangled from reproduction.
Keywords: stem cells; biobank; France; Israel; passage; reproduction
Introduction
In 2007, the biology journal Stem Cells published an article which opened the path
towards the first phase one clinical trial using huES in France to treat infarcted
hearts (Tomescot et al. 2007). When the trial was finally launched on the 21
October 2014 at Georges Pompidou Hospital in Paris, the media1 reported on the
story by focusing on the achievement of the French scientific teams who success-
fully tested this new protocol on a patient after the production of an embryonic stem
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cell bank.2 In the press release written by the public research institute that con-
ducted the basic research, cells are referred to generically as “human embryonic
stem cells,” with no more information. This release stresses the involvement of
French biologists and French surgeons working for public institutions.
In a country where research on human embryonic stem cells has been completely
banned until 2005 and is still tied to sensitive bioethical debates on human embryos
and reproduction, this clinical trial can be seen as the realization of a “national ambi-
tion” (Sleeboom-Faulkner 2011). This national ambition seems to have been able to
hold together scientific excellence and strong national bioethics. However, cells are
never generic. They belong to specific lines, in this case the I6 stem cell line, which
was developed at the Technion Institute of Technology in Israel. This international
scientific collaboration complicates the French national narrative. It also shows
that biobanks are central to not only the production and international exchange of
scientificmaterials, but also to their nationalization. This invites us to discuss anthro-
pological and STS accounts of the links between reproduction and basic science.
In the circulation3 of cell lines through biobanks “repronational histories,” refer-
ring to the ways in which national identities and reproductive politics constitute each
other (Yuval-Davis 1998; Franklin and Inhorn 2016; Roux and Courduriès 2017),4
are central to the emergence of the regenerative medicine field. This suggests that
internationally circulated human embryonic stem cell lines are not entirely “disen-
tangled” from their local provenances, and their reproductive contexts (Gottweiss,
Salter, and Waldby 2009, 35). Inspired by the notion of “co-production” (Jasanoff
2004), this article resulted from a collaboration between two social scientists and
a life scientist. It aims to underline that even when scientific materials such as
human embryonic cells are disentangled from personal reproductive histories,
they are still tied up to reproduction at a national level. We call passages the pro-
cesses through which human embryonic stem cells travel across countries and insti-
tutions. The term “passage” refers to splitting cells from one dish to several dishes in
order to amplify their number. It also has a history in STS (Callon 1986), and we
repurposed it to describe another kind of use and amplification of cells.
After presenting the methods that were used in this collaborative article, we
discuss the notion of disentanglement in stem cell derivation from human
embryos. Then, we underline four passages relating to the co-production of the
I6 line through biobanking circulation. Starting from the French project of huES
cardiac differentiation, we delineate why the team decided to rely on an inter-
national network to import the cells. When the project started in 2005, just after
huES research was authorized under exceptional circumstances, there was no
biobank in France. This is due to a national framework that values reproduction
over basic science and regulates the latter within the understandings of the
former. The second passage implies the presence of numerous supernumerary
IVF embryos biobanks in Israel which has co-produced a very intimate “IVF –
stem cell interface” (Franklin 2006). The third passage concerns the storage of
the I6 in an Israeli research facility that is strongly connected to international
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scientific networks as providers of resources and technologically innovative exper-
tise. Finally, the fourth passage involves the biobanking of the I6 line in the basic
science French laboratory, after they had been imported. As they cross borders from
Israel to France, cells are nationalized through a specific French regulatory bio-
banking regime. In these biobanking practices, cells are passaged in the sense
that their use is amplified while their reproductive meaning is multiplied by circu-
lating from space to space.
Methods
This article results from the multidisciplinary collaboration between two social
scientists and a life scientist. Our collaboration explores the ways in which
researchers across disciplines can tackle shared problems, while not reducing our
topic to one view or the other. Noémie Merleau-Ponty is a sociocultural anthropol-
ogist who researches on IVF and stem cell research in France. Her contribution to
this article is based on her doctoral research conducted at the School of Advanced
Studies in the Social Sciences and on the collection and analysis of primary data
since 2011 (French legislation to be found on the national website “legifrance.
fr,” institutional documentations such as reports from the national committee of
bioethics – Comité consultatif national d’éthique – and the National Biomedical
Agency’s authorization forms of huES cell importation, 22 interviews with
actors of the IVF – stem cell interface in France, as well as participant observations
in basic science facilities between 2011 and 2013). Unlike the Israeli stem cell
sector, the French scientific stem cell context is still understudied from an anthro-
pological perspective, which explains the difference in references with the Israeli
case studied by Sigrid Vertommen.
Sigrid Vertommen is a historian and political scientist who conducts fieldwork-
based research on the political economy of assisted reproduction in Israel/Palestine.
Her contribution to the article is informed through 99 semi-structured interviews
with the various stakeholders who have shaped Israel’s stem cell policies and prac-
tices (including stem cell scientists, embryologists, fertility doctors, representatives
of the Israeli Ministry of Health, members of the National Bioethics Committee,
rabbis, representatives of feminist organizations, CEOs from stem cell companies
and technology transfer companies) and through a close reading of institutional
documents by the National Bioethics Committee, the Israeli Academy of Sciences
and Humanities and the Ministry of Health. This data collection largely took place
in the context of her doctoral research at Ghent University in Belgium, however,
additional interviews were conducted with the Israeli stem cell researcher who
was involved in the production of the I6 stem cell line.
Michel Pucéat is a life scientist, a developmental biologist, who has been involved
in the stem cell field since the authorization to use HUES cells in France in 2005. The
laboratory he runs has used the stem cell line that is the topic of study in this article.
His contribution to this article is based on his involvement in stem cell research
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nationally and internationally. He has given access to primary data, continuously dis-
cussed them with Noémie Merleau-Ponty and Sigrid Vertommen and shared infor-
mation as well as has participated to the writing of this article.
The two social scientists follow what Choy et al. (2009, 380) have stressed when
writing on the Matsutake mushroom: “cultural anthropologists’ interests in global
and multisided phenomena require new kinds of ethnographic methods.” The two
social scientists are collaborating based on their individual fieldwork experiences in
France (N.Merleau-Ponty) and Israel/Palestine (SigridVertomment). The collaboration
between them andMichel Pucéat is rooted in the conviction that if we are to take the co-
production idiom seriously and its “self-conscious desire to avoid both social and tech-
noscientific determinism in S&TS accounts of the world” (Jasanoff 2004, 20), then we
need to implement it in our methods, as well as in our analytical perspectives.
Passages of cells through sites of conservation (biobanks)
The main argument of this article is that the making of the I6 line and its inter-
national travel from Israel to France is co-produced (Jasanoff 2004) by passages
through several biobanks that may entangle or disentangle (Gottweiss, Salter,
and Waldby 2009) repronational contexts (Franklin and Inhorn 2016).
Co-production of basic science and reproduction
The different steps involved in the production of the I6 line from an IVF embryo
and its storage in various biobanks and countries entail several types of “exchange
regimes” (Milanovic, Pontille, and Cambon-Thomsen 2007) – biological, spatial,
legal – all informed by repronational traits. In States of Knowledges, Jasanoff
(2004) introduces the well-known idiom of co-production to explain how
science and society constitute each other without giving primacy to one or the
other. Her proposal stems from a concern that much of the existing research on
science and technology “has not sought to build systematic connections between
the micro-worlds of scientific practice and the macro-categories of political and
social thought” (Id., 18). She continues her critique that
generally, STS work has been less successful than political science in finding places
for human beliefs and imagination, and in accounting for significant economic, tech-
nological and social disparities in the practices of world-making; nor has science
studies paid much attention to what happens when particular epistemic and material
constructions of the world circulate through societies configured by very different his-
torical and material constraints. (Jasanoff 2004, 28)
These suggestions inspire our study of how the I6 line is made and circulated
through global scientific practices within repronational contexts.
Local contexts of human embryonic stem cell science, as underlined by Hauskeller
and Weber (2011), have been extensively studied. Writing on induced pluripotent
stem cells, they indicate that most of the social science work done on stem cells
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highlights the specificities of local contexts, while their article focuses on a more
global scale of analysis, showing the existence of an international community of
scientists. Gottweiss, Salter, and Waldby (2009) have also written about the
global politics of human embryonic stem cell science and suggested that it involves
a process of disentanglement from reproduction and local contexts:
The hESC line is a highly disentangled entity compared with the IVF embryo from
which it was derived. Whereas the IVF embryo is caught up in a dense web of repro-
duction, family relations and social controversy, a gradual process of purification –
donation to clinic and then to laboratory, disaggregation, immortalization, passage
– transforms the embryo into a more properly anonymized, scientific object. It
becomes a neutral, validated entity, denatured of its local significance. (Gottweiss,
Salter, and Waldby 2009, 35)
An institutional process of disconnection and re-identification accompanies the
derivation of cells. The I6 cells have been detached from the original embryo
through an anonymous gift to research, derivation into a cell line, and renaming.
Naming a cell line after an institution following its anonymization from patients
tends to assert this disentanglement. However, saying that these cells no longer
have a history because of the erasure of their past and the production of a narrative
of futurity (Glasner 2005), tells only one side of the story. Franklin (2006) already
noted how, despite its universalizing and totalizing claims, the field of reproductive
biomedicine and stem cell research is also defined by its localized character as it
always depends on a particular context of clinical practice (such as the willingness
of couples to donate their reproductive tissues), ethical regulation (concerning the
status of the human embryo, patient information, informed consent) and a specific
spatio-temporal “fix” of biocapital. These particularities are of course as much local
as they are global, as they are rooted in ongoing histories and global geographies of
science, colonialism, and capitalist modernity. They are particularly clear in IVF-
stem cell interfaces in which
the ‘double reproductive value’ underlying huES cell derivation explores the
meaning and sociological implications of the reproductive value of stem cells ‘in
themselves’ as both can and cannot be separated from their reproductive value in
the context of assisted reproduction. (Franklin 2006, 85)
Passages
The meanings of the word “passages” in this article are multiple. In biology, a
passage of cells is the process of splitting them from one dish to several dishes
in order to amplify their number. This is a mandatory process for huES cells to
grow and this is the meaning implied by Gottweis, Salter and Waldby (ibid.).
For the I6 cell line in Israel, this process started right after the derivation of the
line from the embryo. Then, after their transfer to France, the French scientists
kept growing the cells and continued passaging them. Cells can thus prolong
their life and be expanded as a stock, and they can be available for multiple
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usages. Cells are grown in a medium and some of them are frozen and stored for
future uses, while others are experimented on by adding reagents that interact
with them. Frozen vials can be shipped to different laboratories and countries
through “Material Transfer Agreements” (MTA) that have different contents
depending on the institutions and the various regulations implied. The notion of
“passage” also exists in Science and Technology Studies.
In his article on the sociology of translation, Callon (1986) introduced another
view on “passage.” In this text, he investigates how science and technology struc-
ture power relationships in the domestication of scallops in St Brieuc Bay. He ana-
lyzes how three researchers intervene in St Brieuc, where a controversy erupted
around the population decline of scallops. The researchers manifest their power
in the networks at play by defining “obligatory points of passage” that can fulfill
the hypothetical wishes of different actors (scallops’ survival, fishermen’s
income and scientists’ knowledge) (Callon 1986, 205–206). Similarly, the
meaning of “passage” in this article highlights how different actors with different
identities and interests connect to one another (both nationally and internationally).
By focusing on biobanks as sites through which human embryos and human
embryonic stem cells are cryopreserved and shipped across the world, we
suggest that the co-production of repronational frameworks and the I6 line materi-
alizes through four “passages.” Furthermore, we also suggest that French and
Israeli passages are connected through international exchanges, even if their
logics are very different; and, that French biobanking practices are enabled by
Israeli passages that are nonetheless silenced when the cells are imported into
French settings.
The French IVF/stem cells interface: no cells to passage in 2005
Human embryonic stem cells are undifferentiated cells extracted from blastocysts
(day 5 or 6 embryos). The derivation and cell culture of stem cell lines is the foun-
dation for the production of materials for bioscientific laboratories specialized in
stem cell research. In 1998, the first human embryonic stem cell line was
derived in the USA using an embryo from and in collaboration with Israel
(Thomson et al. 1998). The 2000s saw a new research field emerge from this start-
ing point. Depending on the country, legislations were more or less prone to support
this type of research. In France however, research involving huES was forbidden
until 2005. From 2013, research was only allowed when specific authorizations
were given by the National Biomedical Agency. In 2007, Tomescot and his col-
leagues published an experimental work that had started two years earlier when
French scientists obtained the official authorization to use, but not yet to derive,
human embryonic stem cells in their research (revision of Bioethic law n° 2004-
800 from 6 August 2004 relative to bioethics). In France, huES regulation is orga-
nized under the broader category of research on human embryos, and is strongly
connected to assisted reproductive technologies. Although huES are not embryos
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and leave the “reproductive trail” after their derivation into stem cell lines (Thomp-
son 2005), they are administered through its bioethical framework, resulting in a
distinctive tension: huES science is viewed as dangerous for human embryos
because it considers cells as mere materials. Memmi’s (1996) work analyzed
how French ethical considerations are imbued with reflections on human bodies’
frailty, their biomedical objectification as well as on the need for cures. The
human body is both defined as a “taboo” and an “instrument” (ibid., 28). Similarly,
human embryos are defined in a lose way, which allows different actors to have
different interpretations. In legal and bioethical texts, Raschini (2012, 58) analyzed
the use of “categories of approximation” (approximation catégorielle) that leave
spatial and temporal frontiers of meaning unlimited or open for transformation,
such as the notion of “potential human person.” Indeed, in France, huES science
is regulated through a legal, bioethical and public reproductive framework that
views embryos as neither complete objects of science nor complete subjects of
humanity (Merleau-Ponty 2018).
As it is forbidden to create human embryos for research purposes only (article
L2151-5 of Public Health Code), the cells come from reproductive clinics where
patients keep frozen supernumerary embryos they can give to research. These
embryos are protected by a set of regulations stemming from a tradition of bioethi-
cal discussions as old as the first French birth resulting from IVF in 1982. Indeed,
the French National Consultative Bioethics Committee (CCNE) was created in
1983 by President François Mitterrand. As described through the committee’s
website, it aims at “elucidating scientific progress, raising new issues challenging
society and observing change from the perspective of ethics.” Its first recommen-
dation (CCNE 1984) addressed reflections on embryos and fetuses and their
status as “potential human person.” “This human quality,” the text says, “puts an
obligation on researchers and therapists to respect the embryo. Only the manner
in which this respect is expressed may vary according to the aims pursued.”
(CCNE 1984, 3–4) This “human quality,” continues the recommendation, protects
the embryo against commercial or industrial uses. This exceptionality of the
“human,” which imbues these cells with a status that is more than just biological,
has been kept throughout time and debates, as proven by this extract of a 2010
CCNE recommendation, which recapitulates 26 years of debate and stresses that:
If the embryo in vitro, as soon as it is created, is considered to be a person already, the
ethical issue of the creation of spare embryos and therefore of their possible destruc-
tion, does not even arise: creating spare embryos is unacceptable. If, on the contrary,
the embryo in vitro is seen as nothing more than a bundle of cells, the ethical issue of
creating embryos for research purposes does not arise either: creating embryos for
research is not a problem. Stating that the potential human being is an enigma
means that, after hearing out these two extreme and mutually exclusive positions,
however justified they might be in principle, one chooses to adopt an attitude
which can truly cope with this difficult and essential in between concept: a ‘potential
human being’. (CCNE 2010, 10–11)
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This in-between status consistently re-appears in French bioethics (Jouannet
and Paley-Vincent 2009). As Bateman (2009, 105–6, my translation)
summarizes:
The question ‘who or what?’ suggests that the discussions on the governance of
embryos are understood as an ontological debate: is the embryo a thing that can be
disposed of like any other human tissue, or is it a full person, endowed with full
rights? (…) However, this debate, which is old and more complex than the ‘who
or what’ question, is far from being resolved and might never come to a satisfying
solution for all.
The Second World War and the Nazi machinery of eugenics and extermination
has profoundly oriented French bioethics towards protecting nascent human
lives (Memmi 1996; Rabinow 1999). This protective status can also be explained
by the political power of the dominant religion in the country. Christianity,
especially Catholicism, is well represented in France, and its pro-life and
nature arguments have been addressed and analyzed by social scientists
(Bateman 2002; Mathieu 2013; Merchant 2014). However, this protective
status does not consider embryos to be full-fledged persons, which makes
sense in a country where abortion rights are strong (Boltanski 2004). Since
1975, when abortion was legalized in France, the Veil law allows women
access to “voluntary termination of pregnancy” up to twelve weeks of gestation.
The medical procedure is free and publicly funded.
Taking all these ethical and reproductive considerations on the potential per-
sonhood of human embryos into account, France first banned research on human
embryos or their cells. In the late 1990s and early 2000s, French scientists could
not derive cell lines from IVF embryos or import any of them from abroad, as
the National Biomedical Agency would not authorize such procedures. In 2005,
the ban on huES research was smoothed to support research with therapeutic
goals, however, due to the previous legislation, no stem cell lines were available
in the country. Line derivation is not an easy task and requires significant human
and financial resources. Line derivation is a project which the French team who
published the cardiac differentiation protocol in 2007 had no intention to pursue.
The research was authorized because of its therapeutic goal, not because it was
meant to derive cell lines. Relying on international connections, Israel was one
of the few countries where line derivations had been developed during previous
years. Why specifically this country? This is where the best expertise had been
set. Trying to understand what enabled this expertise opens a wide range of
topics that cannot be reduced to technical skills only. By focusing on two pas-
sages in Israeli biobanks, i.e. the abundant presence of supernumerary IVF
embryos and their availability for research purposes as well as the production
and storage of the I6 line, we unpack the particularity of Israel’s reproductive-
embryonic interface.
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IVF bank: the Israeli IVF-stem cell interface at the frontier
The I6 stem cell line was derived in 2000 at the Technion, Israel’s prestigious Insti-
tute of Technology, by Professor Joseph Itskovitz-Eldor and Dr. Michal Amit. Just
a few years earlier, in 1998, both stem cell researchers collaborated with James
Thomson’s team in Wisconsin to develop the first human embryonic stem cell
lines. As Michal Amit recalled of this collaboration (interview Haifa, 27/07/
2016, our emphasis):
I spent a few months in Wisconsin to learn about the derivation techniques, and then I
came back to Israel. We used five frozen embryos, six days old blastocysts that were
left over from fertility treatment, only three resulted in a successful derivation, the I3,
I4 and I6 lines. These were the first home-grown Israeli stem cell lines. Benjamin
Reubinoff may have been the first Israeli researcher to establish stem cell lines in
2000, but he did it abroad with Alan Trounson and his colleagues at Monash Univer-
sity in Melbourne, and then returned them back to Israel.
Being home-grown or native-born is an important reference in Israeli society,
which in colloquial Hebrew is proudly referred to as being a “Sabra.” A Sabra is
a Jew who is born on Israeli territory rather than in diasporic exile. The term, refer-
ring to the cactus fruit that is known to be tough and prickly on the outside and
sweet on the inside, first appeared in the 1930s and was used by the Zionist move-
ment to celebrate the “New Jew” that emerged in Mandatory Palestine. Unlike the
diasporic “Old Jew” who was often depicted as weak and powerless in Zionist dis-
course, the “New Jew” was portrayed as a fighter, a kibbutz member or farmer who
showed strong, healthy and productivist physical qualities (Almog 2000; Weiss
2002; Davidovitch and Seidelman 2004).
The I6 “Sabra” stem cell line constitutes an interesting entry point to under-
stand the particularity of Israel’s reproductive-embryonic sector, which for over
two decades has been internationally acclaimed for its scientific excellence and
commercial success. Since the field of stem cell research was established in
1998, Israeli scientists such as Benyamin Reubinoff, Joseph Itskovitz-Eldor,
Michal Amit, Karl Skorecki, Dalit Ben-Yosef and Nissim Benvenisty have
been at its “frontier” (Vogel 2002; Barilan and Siegal 2004; Prainsack 2006;
Simonstein 2008; Birenbaum-Carmeli and Carmeli 2010; Ben-Or and Ravitsky
2010; Shalev and Hashiloni-Dolev 2011; Vertommen 2017). In 2002, Science
Magazine lauded Israel as one of the top countries in stem cell research
(UKSCI 2005). The first round of publications on human embryonic stem
cells in the late nineties almost all included Israeli authors and the first two
research teams that succeeded in isolating human embryonic stem cell lines
both involved Israeli researchers (Vogel 2002). Since then, Israel’s stem cell
field has been advancing a broad array of discoveries, including the development
of xeno-free and defined growth media, cell culturing scale-up methods, genetic
manipulation techniques and protocols for induced differentiation of the cells into
desired cell types.
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These scientific developments have taken place in one of the world’s most
lenient regulatory frameworks concerning embryo research. In 1999, Israeli law
makers adopted the “Ban of Genetic Intervention Law,” which put a moratorium
on germ-line genome modification and reproductive cloning in humans that is rene-
gotiated after every five years, while explicitly allowing the use of human embryos
for stem cell research and the production of cloned blastocysts for generating
human tissues (Revel 2000; Israeli Academy of Sciences and Humanities 2001).
Israel’s “fearless, liberal but not immoral embrace of stem cell research,” as Prain-
sack and Firestine (2006, 42) summarized, has been traced back to Judaism’s tol-
erant stance on techno-scientific interventions (Simonstein 2008; Ben-Or and
Ravitsky 2010). Unlike Christianity, Judaism does not oppose human embryonic
stem cell research. Talmudic tradition dictates that life does not begin at the
moment of fertilization, but gradually takes shape after a period of post-implan-
tation development. Before the 40th day of fertilization an embryo is considered
to be maya b’alma or mere water (Steinberg 2003). As Michal Amit (interview
Haifa, 22/02/2012) clarified:
According to Jewish religion an embryo only becomes a person with rights and a soul
after 40 days of fertilization. The five days old embryos that we used for the deri-
vation of the I6 cell line were not seen as human beings, and we were not perceived
as if we were executing living persons by using these embryos for science.
Judaism and Jewish law also attach chief importance to healing and saving lives,
which allows for human interventions into God’s creation. As one famous repro-
ductive biologist from Hadassah Hospital phrased it (interview Jerusalem, 04/03/
2012):
In the Jewish ethos life precedes every law. There is no law that is stronger than life
itself. This is an important ethos. […] Here in Israel life supersedes everything else.
People would go a long way in order to preserve life, to give life, to help cure. So life
has a different meaning here.
Rather than being antagonistic forces, Israel’s religious and scientific communities
have thus forged a remarkable alliance in its policy views and recommendations on
embryonic research (Nahman 2013).
Although Jewish religious prescriptions are obviously crucial in understanding
Israel’s lenient stance on cloning and embryo research, they do not suffice to
explain all. As Prainsack (2006, 189–190) rightfully noted: “Religion alone
tends to explain too much, and therefore it explains too little.” She referred to
the secular segment of Israel’s population that is as permissive in its attitudes
toward embryo research and cloning as its religious counterpart. In addition, she
suggested that whereas Israel’s regulations on this matter takes explicit reference
to Jewish law, in other biomedical matters this is not always the case. In other
words, rather than strictly focusing on cultural and religious narratives of “Jewish-
ness” to understand the production of the I6 cell line, other socio-political entangle-
ments should also be considered. This section analyzes the production and
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circulation of the I6 stem cell line within and across Israel’s repronational “fron-
tiers” by taking into account Zionism’s demographic aspirations and Israel’s
leading position in the global bio-economy (Vertommen 2017).
The I6 stem cell line was derived from one of the tens of thousands spare
embryos that are stored in the freezers of Israeli fertility clinics. Although
Israel’s Ministry of Health is not keen to publicize the exact numbers, it is a
well-known fact that there are large amounts of supernumerary frozen embryos
from fertility treatments in Israeli IVF banks (Raz et al. 2016). According to
Israeli guidelines spare embryos are to be stored for free for five years after
which the patients need to make an embryo disposition decision. Patients can
either pay to keep the frozen embryos in storage, donate the embryos for
medical research, or thaw and destroy the embryos (Israeli Public Health Regu-
lations on In Vitro Fertilization 1987 and MOH circular Guidelines for patients
on use of frozen fertilized oocytes in in vitro fertilization units 2008). It was the
availability of large amounts of spare reproductive tissues and the initial willing-
ness of Israeli couples to donate their embryos for research purposes, which
enabled the early stem cell research discoveries in Israel.5
When asking Michal Amit about the ground-breaking role of Israel in stem cell
research, she replied:
There are “two reasons for Israel’s success: first, the good connections of Professor
Itskovitz on a friendly and scientific level with James Thomson, and the fact that
in Israel you have a lot of surplus embryos. Israel is one of the leading countries
of IVF cycles. So if you do a lot of IVF, you have a lot of surplus embryos that
nobody wants”. (interview Haifa, 22/02/2012)
The coordinator of the Women and Medical Technologies Program of the Israeli
feminist organisation Isha L’Isha, added (interview Haifa, 28/01/2012):
There is kind of a joke among researchers. They say that most of the eggs and
embryos that are circulating in global stem cell research around the world are
coming from IVF clinics in Haifa.
Four of the five original cell lines that were developed in 1998 by Thomson and his
research team were created out of spare IVF embryos from the fertility clinic in
Rambam Medical Center in Haifa, headed by Joseph Itskovitz-Eldor (Thomson
et al. 1998, 1145). Via Dr. Michal Amit, more than a dozen frozen embryos
donated by Israeli couples reached Thomson’s lab in Wisconsin (Vogel 2002).
In Israel, the IVF-stem cell interface has always been very outspoken and
osmotic. Most of Israel’s ground-breaking work in stem cell research has been con-
ducted by fertility specialists who enjoyed a decennia-long, solid experience in
IVF, a reproductive technology that is not only abundantly used, but also fully sub-
sidized by Israel’s pronatalist fertility regime. In an interview with Science Maga-
zine, the Israeli stem cell scientist Reubinoff (quoted in Vogel 2002, 1819)
remarked:
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Given the importance of IVF expertise and connections to the research, it isn’t sur-
prising that Israeli researchers were involved. According to Jewish tradition, to
procreate is very important and there is a lot of support for infertility treatments
and a very large number of IVF clinics in Israel.
Israel has one of the world’s highest number of fertility clinics per capita, and
measured by the number of IVF treatment cycles per capita, Israelis are by far
the biggest consumers of IVF in the world (Sullivan et al. 2013; Birenbaum-
Carmeli 2016).6 Assisted reproductive technologies such as IVF, intracytoplasmic
sperm injection (ICSI), surrogacy, egg donation, egg freezing and preimplantation
genetic diagnosis (PGD) are not only immensely popular and widely accepted in
Israeli society, but most of them are also generously subsidized by the State
(Shalev and Werner-Felmayer 2012; Gooldin 2013). For instance, the Israeli gov-
ernment provides every citizen of the country with an unlimited number of IVF
cycles until the live births of two children within the current relationship (Bire-
nbaum-Carmeli 2004). This pronatalist stance is not only rooted in cultural and reli-
gious commandments of “being fruitful and multiply,” but also in Zionist anxieties
on how to guarantee a Jewish majority in a Jewish State without being demographi-
cally outnumbered by native Palestinians (Portuguese 1998; Kanaaneh 2002;
Nahman 2013; Vertommen 2016). As former Minister of Health Mordechai Gur
commented, when asked about Israel’s exceptionally generous IVF policy: “IVF
is still cheaper than a newcomer” as a means of increasing the size of the population
(quoted in Birenbaum-Carmeli 2004, 900).
Zionism’s core ambition to create and consolidate a Jewish homeland in Israel/
Palestine has not only co-produced a pronatalist demographic logic, but – related
to this – a considerable belief and trust in the therapeutic and diagnostic powers of
medical science and technology. Without them, the Zionist promise to turn the pre-
sumed barren desert into fertile land and bodies could not have been upheld (Prain-
sack 2007). Similar to other colonial endeavors, the Zionist movement has used
medical science and technology to legitimize the colonial settlement of what was
depicted as an empty, backward and disease-ridden land (Efron 2007). Apart from
providing scientific legitimacy to the Zionist project, these technologies were also
required for the creation of a healthy and vitalized Jewish nation after centuries of
collective extermination and what was seen as diasporic decline and degeneration.
(Davidovitch and Seidelman 2004; Efron 2007). Sufian (2006, 390) for instance,
described how Zionist scientists in the early twentieth century “used malariology
to construct intellectual, scientific borders that mobilize the ‘the nation’ while
improving its health.” Birenbaum-Carmeli and Carmeli (2010) and Vertommen
(2017) reached similar conclusions on Israel’s scientific research on human fertility
and stem cells that is often described as “pioneering” or “frontier science.”
Particularly in a context as Israel/Palestine that is increasingly framed as a settler
colonial one (Yuval-Davis and Stasiulis 1995; Veracini 2006; Wolfe 2007, 2016;
Jabary-Salamanca et al. 2012; Shalhoub-Kevorkian 2015; Lentin 2018), it is
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worth unpacking how such metaphors are deployed to describe national imagin-
aries on science and technology. Ceccarelli’s (2013) research on the embeddedness
of the frontier metaphor in American scientific rhetoric described how the term
evokes an agenda of “science as a contest of territory, always on the edge and
on the verge of new discoveries.” What defines the frontier are boundaries that
are never fixed and stable, but always on the verge of being crossed, expanded,
explored, conquered and tamed. While the frontier myth has been glorified as
the essence of America’s success story, it has been rightly criticized in postcolonial
and indigenous STS studies as the source of conquest, exploitation and extermina-
tion of native and racialized populations (Anderson 2002; Harding 2011; Hinterber-
ger 2013; TallBear 2013; Pollock and Subramaniam 2016). Israel’s scientific
frontier mentality can be best captured by the Hebrew term “chutzpah,” which
Senor and Singer (2011, 30), referring back to Leo Rosten’s “The Joys of
Yiddish” (1968), described as “a gall, brazen nerve, effrontery, incredible guts,
the presumption plus arrogance, such as no other word and no other language
can do justice to.” In their popularized analysis of the techno-scientific and com-
mercial success of Israel’s “start-up nation,” Senor and Singer (2011, 106) also
refer to the term bitzu’ism, as “a kind of pragmatism that is at the heart of the pio-
neering ethos and Israel’s entrepreneurial drive.”
This “pioneering” ethos is also present in Israeli discourses and practices of
human embryonic stem cell research, where the belief in medical and scientific pro-
gress tends to overhaul fears of bioethical and societal dystopias. For instance,
when asking one Israeli stem cell researcher in what kind of legal climate the
early stem cell discoveries took place in Israel, she replied (interview Jerusalem,
18/07/2012):
When the first stem cell researchers got involved there was not really a strict legis-
lation. You know, once things were working and many labs were beginning to
derive and many centers were beginning with derivation, there was a need for legis-
lation. Yet in the beginning, there was science before legislation.
While in France such embryonic experimentation would not have been possible,
Israel’s frontier imaginaries did not obstruct this technoscientific practice. Rather
than referring to Jewish or Israeli character idiosyncrasies, such as chutzpah or bit-
zu’ism to explain this, it could be useful to understand it from a (settler)colonial
perspective.
The I6 bank between bioethical leniency and academic entrepreneurialism
After its configuration, the I6 cell line was stored in the WiCell stem cell labora-
tories in Wisconsin, where they fell under the regulation and ownership of T3,
the technology transfer company of the Technion. Michal Amit recalled (interview
Haifa, 27/07/2016):
In those days it was the Technion that approved or disapproved the movement of the
I6 line. The material transfer agreements at the Technion are not very restrictive,
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compared to other research institutions. This is because we want the knowledge and
materials to be used by other institutions, so that they can further develop.
Unlike in many other countries where the export of stem cell lines is decided on a
national level, in Israel this decision is made by the individual research institute
without public discussion or the involvement of national committees on medical
ethics. As Itskovitz and Amit were hopeful and determined to quickly develop
clinical applications in the field of cell repair, they were also keen to export
Israeli stem cells for biomedical research by cooperating with stem cell laboratories
in other countries (Gross 2001, 582). In the early 2000s the Technion was therefore
one of the few centers in the world where stem cell researchers from more restric-
tive countries “would do their shopping” (Gross 2003, 244). In the case of the I6
cell line, this led to several controversies. In 2003, for instance, the stem cell
line was exported to Bonn University in Germany for research on nerve cells
causing moral criticism. The German reluctance to allow research with huES cell
lines was rooted in Kantian views on man as an end in himself, and in painful col-
lective memories of Nazi experiments on human beings. This resulted in remark-
able discussions on the morality of human embryonic stem cell research in
which Israeli bioethicists urged their German counterparts for calm and moder-
ation. The Israeli bioethics expert Asa Kasher told the newspaper (Ha’aretz, 09/
01/2003): “Perhaps we, the Jews of Israel, are the only ones who can tell [the
Germans] them that on this matter, they are exaggerating.”
Today, the I6 cell line is still property of the Technion, but the exclusive license is
with Accellta, a spin off company from the Technion. Accellta was founded in 2012
by Amit and Itskovitz to provide customized solutions for mass production of
human embryonic and induced pluripotent stem cells for drug discovery, regenera-
tive medicine and research. Since then, the export of the I6 line has become costlier.
While in 2005 the French team from INSERM could still import the cell line
without any cost except the shipping costs, this has changed since 2012. Michal
Amit (interview Haifa, 27/07/2016) remarked:
Last time, few months ago when I had to arrange an MTA for the cells, the price was
1300 dollars plus shipping costs, which is really not that much if you come to think of
all the tender love and care and money that we have put in deriving these cells.
The stem cell sector constitutes a key sector in Israel’s bio-economy that since the
late seventies has been positioning itself as a major player in the global market of
biomedical research and development, with a special focus on healthcare (Prain-
sack and Firestine 2006; Vertommen 2017). Accelta is one of Israel’s 18 biotech
companies that are currently developing and marketing cell-based regenerative
therapies, with Pluristem, Cell Cure, Gamida Cell, Brainstorm and Kamidastem
being the most promising ones. Most of Israel’s stem cell companies are former
start-up companies from Israeli universities and research centres that are known
to be strongly oriented towards the market. Messer-Yaron (2011, 17) stated that
Israeli research institutions were among the first in the world to commercialize
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their academic discoveries through the successful creation of technology transfer
companies, prompting her to term Israel not the only, but “by all measures- a
best practice example” in matters of technology transfer. Israeli tech transfer com-
panies, such as T3 from the Technion are among the world’s top in terms of reven-
ues and patent holders in the field of medical devices and bio-pharmaceuticals
(Israel’s Foreign Investments and Industrial Cooperation Authority 2016). From
the early stages in the research process, Israeli researchers are urged to commercia-
lize their knowledge production through the creation of patents or spin offs (Oliver
2004).
To understand the production of the I6 line one needs to understand the particu-
larity of Israel’s repronational IVF-stem cell interface. Similarly, the reception of
these cells in France is not only about importing a global material, but also natio-
nalizing it.
Nationalizing the resource: authorization of importation and lab
biobanking
What happens when French biologists ask for an authorization to import huES from
abroad? They have to fill in a lot of documentation for the National Biomedical
Agency to verify the legitimacy of the demand. The National Biomedical
Agency asks whether the lines are registered at the UK Stem Cell Bank or the
National Institutes of Health in the USA (NIH). These two institutions play a
powerful and active role in standardizing practices, through which a bioscientific
community works for the promotion of a new field of research (Webster and Eriks-
son 2008; Eriksson and Webster 2015).
The importation of cell lines is also subject to national criteria that have nothing
to do with standardization of global materials. A major therapeutic progress must
be underlined, and research strictly oriented towards the widening of knowledge
is not authorized (article L2151-5 of the Public Health Code). Furthermore,
article 16 and 16-8 of the Civil Code must be respected, stating the “primacy of
the person,” forbidding any “violation of its dignity” and “guaranteeing respect
for the human being from the beginning of its life.” Regarding in vitro human
embryos, these elements point to the “anonymous” and “free gift” to research
from “a couple” or “the surviving member of this couple” who gave a “consent”
after having abandoned their “parental project” and after having been informed
of other options, like gift to another couple or destruction. How can the National
Biomedical Agency verify if all these criteria have been respected? Only some
of the criteria can be documented, such as the therapeutic goal, the consent, the
anonymity and the free gift.
The clauses on the “primacy of the person,” its “dignity” or the “beginning of
life,” however, are more difficult to verify. These notions relate to a specific
French framework that we addressed at the beginning of this article. The logic
behind the notion of “potential human person” sustained an open but protective
352 N. Merleau-Ponty et al.
view on human embryos. However, this notion depends on the national context, for
example, if we think of the United Kingdom where research is authorized until 14
days of development on what is called the “pre-embryo” (Franklin 2013; Warnock
1985; Mulkay 1997; Bigg 2017) as well as of other frames across the world (Jasan-
off 2005; Bharadwaj 2012; Hurlbut 2017; Thompson 2013). Moreover, the refer-
ence to the “couple” implies a very specific set of norms that are stressed in the
Public Health Code (articles L2141-1 and L2141-2). Patients have to be heterosex-
ual, within a specified procreative age, and be married / have been a couple for at
least two years. Again, this is very specific to France and a lot of countries have
opened assisted reproductive technologies to single persons and/or same sex
couples. In Israel, for example, single women can access fertility treatments and
it is perfectly conceivable that the embryo used to derive the I6 line was gifted
by someone who was single.
Interestingly, the authorization to import a huES line, given by the National Bio-
medical Agency, based on the above law articles, is neither the recognition of other
bioethical frames nor a complete recognition of a standardized global material for
research. The authorization is a process of nationalization that reinvents the cells as
French by framing their importation in specific words. The Civil Code’s ontological
vocabulary has no reference to a sociological reality outside of France. These words
can be seen as drivers for new meanings. When cells enter the French territory, they
are inscribed in a set of institutional practices that give them new meaning relating
to French history, bioethics and legislation. This ontological production is not only
discursive but has very practical consequences.
The Israel number 6 cell line was nationalized by regulating laboratory biobank
management. Even if the process of derivation has completely transformed cells
which are no longer embryos, even if the cells come from a different country
with a different history, economy and religion, these cells gain a status of special-
ness as soon as they enter French territory. An inspector of the National Biomedical
Agency commented that their traceability must be “total.” Penal rules are very
clear, and anyone who breaks these rules risks a fine of up to 30 000 euros and
two years of imprisonment (article L2163-7 of public health Code and article
511-19-2 of penal Code). “It is a very delicate context relating to the Human and
human reproduction,” commented the inspector during an interview with
Merleau-Ponty (28th of July 2015). This sentence tightly binds stem cells to
their IVF past. It also stresses the delicate balance between research goals and
French representations on human embryos.
Cells’ traceability can be established in several ways. For example, experiments
using huES must be written in special laboratory notebooks, while all other exper-
iments with different materials, human and non-human, can be written in the same
notebook. Storage procedures must be clearly identified, and laboratories are
required to provide maps of their facilities and clear identification of where the
cells are stored. Whilst special incubators for cell culture are not mandatory, the
basic science laboratory which cultured the I6 did so in a specific one, as the
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laboratory space dedicated to cell culture was big enough. Similarly, the huES
bank, the physical tank, was in a special room away from all the other cells,
both human and animal. Moreover, when the inspector narrated how he inspects
a laboratory, he stressed that he does not look at the other cells’ management
(either human or other animals) but concentrates all his attention on the huES
lines. Once within French territory these cells are connected to a new ontological
apparatus which inscribes them in a context that has nothing to do with personal
biographies or Israeli layers, but which relates to French bioethics.
Discussion
When the press release referred to the French clinical trial as having used “human
embryonic stem cells,” it certainly enacted a “disentangled” version of stem cell
science from reproductive dynamics (Glasner 2005; Gottweiss, Salter, and Waldby
2009). However, when analyzing where the cells originated from, reproduction
comes back to the forefront, not as a personal biographical, but as a repronationalist
dynamic. Repronationalism, in its variegated shapes and forms, underlines how the
rise of stem cell science is part of a country’s national identity and political economy,
shaped through reproductive policies and practices (Yuval-Davis 1998; Zanini 2011;
Nahman2013; Franklin and Inhorn2016;RouxandCourduriès 2017;Wahlberg 2018).
Furthermore, looking at which cells were used also opens up a history of travel
across two national frameworks, the French and the Israeli one. Following transna-
tional connections of biobanks from France to Israel and back, we have delineated
how the cells are co-produced within different repronational contexts while circulat-
ing across the world. If the derivation of a human embryonic stem cell line implies a
biological transformation of the human embryo, as well as the use of these cells in
protocols which have little to do with reproduction, this article has shown that the
reproductive framings of these cells inform their regenerative future. Moreover,
the global circulation of these cells is not a disappearance of local contexts which
are, on the contrary very much involved in the transnational logics.
The French basic science laboratory that started its research in 2005 relied on
international collaborations as French bioethics and regulations had prevented
the production of stem cell lines based on a specific reproductive understanding
of embryos as “potential human persons.” The cells used in the scientific protocols
came from Israel. The embryo that was given to produce the stem cell line was
transformed into a biological material named “Israel number 6” in a context
where numerous supernumerary embryos were available to donation and stem
cell science associated with bioethical leniency and academic entrepreneurialism.
The international character of the I6 stem cell line is an entanglement of national
contexts (the French and the Israeli one) in which reproduction plays a central
role, albeit in different ways. The production and circulation of the line from one
country to the other materializes through the usage of several types of conservation
sites, which accompany the passaging of the cells.
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The meaning of passage refers not only to the ways in which scientists build net-
works and solve problems (Callon 1986), but also to the ways in which scientific
practices of stem cell biology are co-produced (Jasanoff 2004) by repronational his-
tories (Franklin and Inhorn 2016). The notion of passage highlights the intertwining
of these different aspects in the storage of cells in several biobanks. The absence of
cells in 2005 in France can be viewed as a passage as it results from the strong link
between embryos, reproduction and French bioethics that views biologization as a
threat to humanization. The importation of cells from Israel to France enacts co-
productive dynamics that connect “the micro-worlds of scientific practice and the
macro-categories of political and social thought” (Id., 18). When biologists tick
boxes on the French importation permits, they connect cells to French reproductive
regulations that have little to do with the Israeli IVF-stem cell interface that co-pro-
duced the cells. When the inspector of the National Biomedical Agency explains
how he visits stem cells labs and verifies notebooks and biobank management,
he justifies his practice by referring to “the Human and human reproduction,”
reproducing a French nationalized version of reproduction in the stem cell lab.
Each cell passage within biology practices is the reproduction of sameness and
difference, as the cells divide into two versions of themselves and microDNA
changes might occur. Passaging cells across sites, institutions and countries is
about circulating a common material for research (the I6 line) while modifying
its understanding in two different repronational contexts and a global market.
This focus on long-term genealogy contributes to the ongoing critique of the
bench to bedside view of bioscientific translation (Wainwright et al. 2006; Cribb
et al. 2008; Martin, Brown, and Kraft 2008; Jent 2017). By researching what
makes basic research practices possible, local understandings of reproduction
and national histories of science and technology arise. Within global dynamics,
bioscientists deal with national frameworks which have strong stances on what
embryos and their stem cells are, as well as the reconfigurations involved in passa-
ging materials from one country to the other.
Notes
1. http://presse.inserm.fr/therapie-cellulaire-de-linsuffisance-cardiaque-premiere-implantation-de-
cellules-cardiaques-derivees-de-cellules-souches-embryonnaires-humaines/17502/
2. In this article, the term “biobank” is used with a wide definition that is not restricted to a definition
stemming from national and international regulations. First of all, this text builds on the context
of the early 2000’s when such regulations were still in the making. In 2005, in the huES world,
the only institutionalized biobank was the UK stem cell bank from Glyn Stacey. But, huES lines
were nonetheless derived, stored and circulated across countries. In this text, we use the definition
of Milanovic, Pontille, and Cambon-Thomsen (2007, 3). When referring to biological samples
they write that
there is no consensus on terminology in regard to these resources, which are designated by
diverse terms: collections, biological resource centres, biological databases, bioreposi-
tories, biobanks, to name only a few. ‘Biobank’ will be the term used throughout this
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paper for such organised collections. (…) A biobank can be generically defined as a group
of biological samples that may consist of any tissue or fluid containing nucleated cells
(solid tissues, blood, saliva, etc.) that are associated with computerized files generally
including the origin of the donors, clinical data and biological data.
For example, Michel Pucéat’s laboratory, which imported and stored the I6 cells was not strictly
speaking a biobank but a “site of conservation” with authorizations from the Agency of Biome-
dicine to import the cells, store them and research with them. The origin of donors is anonymous
in that case, and the clinical data are unknown apart from negative virology. As a “site of con-
servation,” the laboratory has to respect some rules about where the cells are stored in the facility,
in a certain kind of room and container, using a certain kind of cell registry. These rules are not as
plentiful as the ones used to regulate and legally define “biobanks” in a hospital or what is called
in France “clinical investigation centers” where the cells that are banked may be used for cell
transplantation or just genetic screening or, eventually, for research in academic labs.
3. The word “circulation” is a tribute to a conference were an early version of this paper was
presented. Biocircularities: Lives, times and technologies, organized by Branwyn Poleykett
and Karen Jent, CRASSH, University of Cambridge. 31-03-2017/01-04-2017
4. Franklin and Inhorn (2016) introduced the term repronationalism to describe “how each country
uses reproductive policy to shape its national identity, while similarly expressing its national
identity through its reproductive policy” (Also see, Franklin (2016).
5. There are no national statistics on what happens with supernumerary embryos after being stored
for five years. Yet, according to recent finding by Raz et al. (2016) the donation rate for research is
very low in Israel.
6. The number of IVF cycles in Israel totaled 34,538 in 2010 compared to nearly 32,000 during
2014 and 18,000 in 2000. (http://www.jpost.com/Health-and-Science/Number-of-IVF-births-
in-Israel-risesin-last-decade).
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